Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;9(Suppl 2):S295-S302.
doi: 10.21037/tau.2019.09.36.

Non-conventional therapies for Peyronie's disease: what is the evidence for efficacy?

Ishan Aditya  1 , Jethro C C Kwong  1 , Yonah Krakowsky  2 , Ethan D Grober  2
Affiliations

Non-conventional therapies for Peyronie's disease: what is the evidence for efficacy?

Ishan Aditya et al. Transl Androl Urol. 2020 Mar.

Abstract

Background: In recent years, there has been a surge in non-conventional therapies for Peyronie's disease (PD). With increasing interest in these novel therapies, we conducted a narrative review to explore the efficacy and safety of these treatments to provide clarity for patients and providers.

Methods: A literature search was conducted to find studies describing non-conventional treatments of PD. These treatments were defined as those within the standard of care, including intralesional therapies and surgical options.

Results: A total of 14 studies were found. Non-conventional therapies included platelet-rich plasma (PRP), hyaluronic acid (HA), combination therapy of PRP and HA, extracorporeal shockwave therapy (ESWT), stem cell therapy (SCT), mycophenolate mofetil (MMF), and H-100. Most studies were limited to animal models and reported modest improvements in angulation and erectile function. Complication rates and cost of each treatment were infrequently reported.

Conclusions: There is limited evidence supporting non-conventional therapies for PD. As such, they are currently not recommended in clinical guidelines.

Keywords: Peyronie’s disease (PD); erectile function; non-conventional therapy; penile curvature.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The focused issue “Contemporary Issues and Controversies in Men’s Health” was commissioned by the editorial office without any funding or sponsorship. Dr. Grober & Dr. Krakowsky: Consultants—Paladin Labs. The other authors have no conflicts of interest to declare.

References

    1. Yafi FA, Pinsky MR, Sangkum P, et al. Therapeutic advances in the treatment of Peyronie's disease. Andrology 2015;3:650-60. 10.1111/andr.12058 - DOI - PubMed
    1. Lue TF, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23. 10.1111/j.1743-6109.2004.10104.x - DOI - PubMed
    1. Stuntz M, Perlaky A, des Vignes F, et al. The prevalence of Peyronie's disease in the United States: a population-based study. PLoS One 2016;11:e0150157. 10.1371/journal.pone.0150157 - DOI - PMC - PubMed
    1. Culha MG, Erkan E, Cay T, et al. The effect of platelet-rich plasma on Peyronie’s disease in rat model. Urol Int 2019;102:218-23. 10.1159/000492755 - DOI - PubMed
    1. Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol 2018;59:61-5. 10.4111/icu.2018.59.1.61 - DOI - PMC - PubMed